{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T23:54:56Z","timestamp":1778975696284,"version":"3.51.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cld.2023.05.009","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T16:01:32Z","timestamp":1688745692000},"page":"997-1022","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Test All for Hepatitis B Virus"],"prefix":"10.1016","volume":"27","author":[{"given":"Katerina","family":"Roma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Dossaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubaba","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooba","family":"Laeeq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Brosgart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cld.2023.05.009_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/apt.16828","article-title":"Review article: hepatitis B-current and emerging therapies","volume":"55","author":"Yardeni","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/hep.31782","article-title":"An updated assessment of chronic hepatitis B prevalence among foreign-born persons living in the United States","volume":"74","author":"Wong","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis B: accessibility, durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hep.32314","article-title":"Getting to HBV cure: the promising paths forward","volume":"76","author":"Fung","year":"2022","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/v9060139","article-title":"Detection of HBV covalently closed circular DNA","volume":"9","author":"Li","year":"2017","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tracli.2017.06.014","article-title":"Occult hepatitis B infection and transfusion-transmission risk","volume":"24","author":"Candotti","year":"2017","journal-title":"Transfus Clin Biol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib8","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jam.15351","article-title":"Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: a literature review","volume":"132","author":"de Almeida","year":"2022","journal-title":"J\u00a0Appl Microbiol"},{"issue":"8","key":"10.1016\/j.cld.2023.05.009_bib9","first-page":"582","article-title":"The pigeonhole of occult hepatitis B","volume":"52","author":"Dindoost","year":"2014","journal-title":"Acta Med Iran"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","article-title":"Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions","volume":"152","author":"Loomba","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.05.009_bib11","doi-asserted-by":"crossref","first-page":"2931402","DOI":"10.1155\/2018\/2931402","article-title":"Recent advances in HBV reactivation research","volume":"2018","author":"Guo","year":"2018","journal-title":"BioMed Res Int"},{"issue":"RR-16","key":"10.1016\/j.cld.2023.05.009_bib12","first-page":"1","article-title":"A\u00a0comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults","volume":"55","author":"Mast","year":"2006","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"key":"10.1016\/j.cld.2023.05.009_bib13","unstructured":"MMWR. Newborn Hepatitis B Vaccination Coverage Among Children Born January 2003--June 2005 --- United States. CDC. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5730a3.htm#:\u223c:text=Hepatitis%20B%20vaccine%20was%20first,the%20United%20States%20(1)."},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and testing for hepatitis B virus infection: CDC recommendations \u2014 United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IM9.0000000000000089","article-title":"Renaming NAFLD to MAFLD: advantages and potential changes in diagnosis, pathophysiology, treatment, and management","volume":"4","author":"Rui","year":"2022","journal-title":"Infectious Microbes & Diseases"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib16","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/apt.14506","article-title":"Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative","volume":"47","author":"Chan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib17","first-page":"4","article-title":"Metabolic dysfunction-associated fatty liver disease from definition to complications Review Article","volume":"6","author":"Azat","year":"2021","journal-title":"Medical Journal of Viral Hepatitis (MJVH)"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4103\/ijmr.IJMR_1456_17","article-title":"Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: an increasing concern","volume":"149","author":"Dhamija","year":"2019","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.cld.2023.05.009_bib19","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cld.2023.05.009_bib20","doi-asserted-by":"crossref","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib21","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0039-1678728","article-title":"Current knowledge of occult hepatitis B infection and clinical implications","volume":"39","author":"Yip","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2023.05.009_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.cld.2023.05.009_bib24","doi-asserted-by":"crossref","first-page":"a021550","DOI":"10.1101\/cshperspect.a021550","article-title":"Hepatitis D virus coinfection and superinfection","volume":"4","author":"Negro","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"7","key":"10.1016\/j.cld.2023.05.009_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"KIM","year":"2010","journal-title":"Respirology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2016.0024","article-title":"Prevention of hepatitis B reactivation in the setting of immunosuppression","volume":"22","author":"Pattullo","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Perrillo","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib28","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","author":"Reddy","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jhep.2007.07.017","article-title":"Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI)","volume":"47","author":"Thomas","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.05.009_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/PROM.S226936","article-title":"Impact of stigma on people living with chronic hepatitis B","volume":"11","author":"Smith-Palmer","year":"2020","journal-title":"Patient Relat Outcome Meas"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib31","first-page":"313","article-title":"[Clinical value of health-related quality of life evaluation in community patients with hepatitis B]","volume":"25","author":"Chen","year":"2017","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/gut.45.2.295","article-title":"Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease","volume":"45","author":"Younossi","year":"1999","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib33","doi-asserted-by":"crossref","first-page":"100556","DOI":"10.1016\/j.aohep.2021.100556","article-title":"Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and C","volume":"27","author":"Golabi","year":"2022","journal-title":"Ann Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2023.05.009_bib34","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.cgh.2018.02.037","article-title":"Effects of treatment of chronic hepatitis B virus infection on patient-reported outcomes","volume":"16","author":"Younossi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.009_bib35","unstructured":"Organization WH. Hepatitis: How can I protect myself from hepatitis B? 2023. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/hepatitis-b-how-can-i-protect-myself#:\u223c:text=HBV%20is%20spread%20by%20contact,baby%20at%20the%20birth%20(perinatal)."},{"issue":"9","key":"10.1016\/j.cld.2023.05.009_bib36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.14309\/ajg.0000000000000651","article-title":"Prevalence of chronic hepatitis B virus infection in the United States","volume":"115","author":"Lim","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11901-017-0364-8","article-title":"Epidemiology and treatment of hepatitis B in prisoners","volume":"16","author":"Smith","year":"2017","journal-title":"Curr Hepatol Rep"},{"issue":"5","key":"10.1016\/j.cld.2023.05.009_bib38","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global epidemiology of chronic liver disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.009_bib39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology. Jan"},{"issue":"21","key":"10.1016\/j.cld.2023.05.009_bib40","article-title":"Extrahepatic manifestations of chronic HBV infection and the role of antiviral therapy","volume":"11","author":"Mazzaro","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.rdc.2009.03.006","article-title":"Hepatitis B-related autoimmune manifestations","volume":"35","author":"Cacoub","year":"2009","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"10.1016\/j.cld.2023.05.009_bib42","first-page":"451","article-title":"The extrahepatic manifestations of hepatitis B virus","volume":"18","author":"Baig","year":"2008","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"issue":"8","key":"10.1016\/j.cld.2023.05.009_bib43","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/jvh.12892","article-title":"Hepatitis B virus and risk of non-Hodgkin lymphoma: an updated meta-analysis of 58 studies","volume":"25","author":"Li","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3748\/wjg.v28.i1.76","article-title":"Viral hepatitis in 2021: the challenges remaining and how we should tackle them","volume":"28","author":"Dunn","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.009_bib45","unstructured":"Charuchandra S. Most Countries Not on Track to Eliminate Hepatitis B and C by 2030. https:\/\/www.hepmag.com\/article\/countries-track-eliminate-hepatitis-b-c-2030."},{"issue":"8b","key":"10.1016\/j.cld.2023.05.009_bib46","first-page":"13","article-title":"Towards the elimination of hepatitis B and hepatocellular carcinoma","volume":"108","author":"Spearman","year":"2018","journal-title":"S\u00a0Afr Med J"},{"issue":"10161","key":"10.1016\/j.cld.2023.05.009_bib47","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2023.05.009_bib48","unstructured":"Observatory CFsP. CDA Foundation\u2019s Polaris Observatory. https:\/\/cdafound.org\/polaris\/."},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib49","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep4.1627","article-title":"A\u00a0population-based intervention to improve care cascades of patients with hepatitis C virus infection","volume":"5","author":"Scott","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2023.05.009_bib50","article-title":"Practice transformation in HIV primary care: perspectives of coaches and champions in the southeast United States","volume":"12","author":"Kay","year":"2021","journal-title":"J\u00a0Prim Care Community Health"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12976-017-0057-6","article-title":"Markov modeling in hepatitis B screening and linkage to care","volume":"14","author":"Sehr","year":"2017","journal-title":"Theor Biol Med Model"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s13187-011-0252-9","article-title":"Destigmatizing hepatitis B in the asian American community: lessons learned from the san Francisco Hep B free campaign","volume":"27","author":"Yoo","year":"2012","journal-title":"J\u00a0Cancer Educ"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib53","first-page":"538","article-title":"San Francisco Hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer","volume":"36","author":"Bailey","year":"2011","journal-title":"J\u00a0Community Health"},{"issue":"7","key":"10.1016\/j.cld.2023.05.009_bib54","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4254\/wjh.v14.i7.1333","article-title":"Challenge of managing hepatitis B virus and hepatitis C virus infections in resource-limited settings","volume":"14","author":"Said","year":"2022","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J\u00a0Hepatol"},{"issue":"10003","key":"10.1016\/j.cld.2023.05.009_bib56","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.cld.2023.05.009_bib57","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.009_bib58","first-page":"S3","article-title":"EASL international consensus conference on hepatitis B. 13-14 september, 2002 geneva, Switzerland. Consensus statement (long version)","volume":"39","author":"de Franchis","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1590-8658(01)80062-1","article-title":"Hepatocellular carcinoma: global epidemiology","volume":"33","author":"Tabor","year":"2001","journal-title":"Dig Liver Dis"},{"issue":"9859","key":"10.1016\/j.cld.2023.05.009_bib60","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"issue":"43","key":"10.1016\/j.cld.2023.05.009_bib61","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.3748\/wjg.v27.i43.7497","article-title":"Hepatitis B: who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases","volume":"27","author":"Kawanaka","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cld.2023.05.009_bib62","unstructured":"Organization WH. Hepatitis B. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b. Accessed November 20, 2022."},{"issue":"17","key":"10.1016\/j.cld.2023.05.009_bib63","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.cld.2023.05.009_bib64","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2023.05.009_bib66","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7150\/ijms.71737","article-title":"Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients","volume":"19","author":"Wang","year":"2022","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cld.2023.05.009_bib67","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2022.0342","article-title":"Development of hepatocellular carcinoma in untreated and treated patients with chronic hepatitis B virus infection","author":"Lin","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib69","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3350\/cmh.2016.0045","article-title":"The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy","volume":"22","author":"Varbobitis","year":"2016","journal-title":"Clin Mol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.05.009_bib70","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jvh.13185","article-title":"The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria","volume":"26","author":"Sinn","year":"2019","journal-title":"J\u00a0Viral Hepat"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib71","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen","year":"2020","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib72","first-page":"939","article-title":"Pharmacological therapeutics: current trends for metabolic dysfunction-associated fatty liver disease (MAFLD)","volume":"9","author":"Prasoppokakorn","year":"2021","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib73","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib74","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12072-008-9045-6","article-title":"Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)","volume":"2","author":"Hann","year":"2008","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib76","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2021.12.286","article-title":"Inhibition of viral replication reduces transcriptionally active distinct hepatitis B virus integrations with implications on host gene dysregulation","volume":"162","author":"Hsu","year":"2022","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.cld.2023.05.009_bib77","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2021.07.036","article-title":"Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update","volume":"20","author":"Martin","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib78","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/apt.15581","article-title":"Review article: clinical pharmacology of current and investigational hepatitis B virus therapies","volume":"51","author":"Smolders","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib79","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2023.05.009_bib80","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.14356","article-title":"Future treatments for hepatitis delta virus infection","volume":"40","author":"Asselah","year":"2020","journal-title":"Liver Int"},{"issue":"15","key":"10.1016\/j.cld.2023.05.009_bib81","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: first approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib82","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2023.05.009_bib83","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.cld.2023.05.009_bib84","first-page":"223A","article-title":"Dual-gRNAs and gRNA-microRNA (miRNA)-gRNA ternary cassette combined CRISPR\/Cas9 system and RNAi approach promotes the clearance of HBV cccDNA","volume":"62","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.05.009_bib85","first-page":"782A","article-title":"The combination effects of CRISPR\/Cas9 and APOBEC3B editing on HBV cccDNA formation","volume":"66","author":"Shi","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11901-020-00523-z","article-title":"Role of core\/capsid inhibitors in functional cure strategies for chronic hepatitis B","volume":"19","author":"Hui","year":"2020","journal-title":"Current Hepatology Reports"},{"issue":"12","key":"10.1016\/j.cld.2023.05.009_bib87","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2023.05.009_bib88","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1002\/hep4.2095","article-title":"Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B","volume":"6","author":"Yuen","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.cld.2023.05.009_bib89","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen","year":"2019","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.cld.2023.05.009_bib91","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/j.gastro.2020.02.058","article-title":"Safety and efficacy of 48 Weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection na\u00efve to nucleos(t)ide therapy","volume":"158","author":"Bazinet","year":"2020","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.cld.2023.05.009_bib92","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1016\/j.cgh.2019.09.038","article-title":"Efficacy of lenvervimab, a recombinant human immunoglobulin, in treatment of chronic hepatitis B virus infection","volume":"18","author":"Lee","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.05.009_bib93","unstructured":"Gane E, Jucov A, Dobryanska M, et\u00a0al. Safety, tolerability, and antiviral activity of the siRNA VIR 2218 in combination with the investigational neutralizing monoclonal antibody VIR 3434 for the treatment of chronic hepatitis B virus infection: Preliminary results from the phase 2 MARCH trial. American Association For The Study Of Liver Diseases (AASLD). 2022. https:\/\/www.natap.org\/2022\/AASLD\/AASLD_19.htm."},{"issue":"39","key":"10.1016\/j.cld.2023.05.009_bib94","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","article-title":"Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study","volume":"32","author":"Gaggar","year":"2014","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.cld.2023.05.009_bib95","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00011-010-0233-1","article-title":"Intrahepatic levels of PD-1\/PD-L correlate with liver inflammation in chronic hepatitis B","volume":"60","author":"Chen","year":"2011","journal-title":"Inflamm Res"},{"issue":"49","key":"10.1016\/j.cld.2023.05.009_bib97","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1016\/j.vaccine.2008.09.056","article-title":"The global impact of vaccination against hepatitis B: a historical overview","volume":"26","author":"Zanetti","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.cld.2023.05.009_bib98","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cld.2016.06.006","article-title":"Epidemiology of hepatitis B virus infection and impact of vaccination on disease","volume":"20","author":"Nelson","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2023.05.009_bib99","unstructured":"Control CfD. Heplisav-B\u00ae (HepB-CpG) vaccine. US department of Health and Human Services Center for Disease Control and Prevention. 2023. 2023. https:\/\/www.cdc.gov\/vaccines\/schedules\/vacc-updates\/heplisav-b.pdf."},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ndt\/gfac039","article-title":"A\u00a0real world comparison of HepB (Engerix-B\u00ae) and HepB-CpG (Heplisav-B\u00ae) vaccine seroprotection in patients receiving maintenance dialysis","volume":"38","author":"Manley","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.cld.2023.05.009_bib101","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10620-020-06437-6","article-title":"Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease","volume":"66","author":"Amjad","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.cld.2023.05.009_bib102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14760584.2021.1908133","article-title":"CpG-adjuvanted hepatitis B vaccine (HEPLISAV-B\u00ae) update","volume":"20","author":"Lee","year":"2021","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.cld.2023.05.009_bib103","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.vaccine.2017.07.046","article-title":"Hepatitis B vaccines: WHO position paper, July 2017 - recommendations","volume":"37","author":"World Health","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cld.2023.05.009_bib104","unstructured":"Prevention CfDCa. CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. 2013."},{"key":"10.1016\/j.cld.2023.05.009_bib105","unstructured":"Prevention CfDCa. Adult immunization schedule. Center for Disease Control and Prevention 2023. https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fschedules%2Fhcp%2Fadult.html."},{"key":"10.1016\/j.cld.2023.05.009_bib106","unstructured":"Hepatitis B Foundation Vaccine Schedule. https:\/\/www.hepb.org\/prevention-and-diagnosis\/vaccination\/guidelines-2\/#international."},{"issue":"3","key":"10.1016\/j.cld.2023.05.009_bib107","doi-asserted-by":"crossref","first-page":"241","DOI":"10.14218\/JCTH.2016.00014","article-title":"Hepatitis B management in the pregnant patient: an update","volume":"4","author":"Ayoub","year":"2016","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2023.05.009_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6701a1","article-title":"Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization Practices","volume":"67","year":"2018","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"10","key":"10.1016\/j.cld.2023.05.009_bib109","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/ajg.2016.296","article-title":"Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B","volume":"111","author":"Chang","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2023.05.009_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations - United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"issue":"1 Suppl","key":"10.1016\/j.cld.2023.05.009_bib111","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J\u00a0Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326123000697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:00:45Z","timestamp":1761069645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326123000697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1089326123000697"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.009","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Test All for Hepatitis B Virus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}